Search for other works by this author on: ...
University of Arkansas for Medical Sciences, Little Rock, AR, United States ...
Major Finding: Agonism of gasdermin D (GSDMD) triggers pyroptosis in cancer cells and inhibits tumor growth. Concept: The efficacy of the GSDMD agonist, DMB, is dependent on tumor cell GSDMD ...
Healthcare services company Cardinal Health will acquire Integrated Oncology Network (ION) for about $1.12 billion. A physician-led operator of community cancer centers, ION includes more than 50 ...
The development of second-generation covalent “off”-state KRAS G12C inhibitors is taking off. Two candidates, D3S-001 and divarasib, highlighted at the 2024 ESMO Congress, show better efficacy, with ...
Search for other works by this author on: ...
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Search for other works by this author on: ...
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, ...
University of Nebraska Medical Center, Omaha, NE, ...
The FDA approved pembrolizumab (Keytruda; Merck) with chemotherapy as a first-line treatment for advanced or metastatic malignant pleural mesothelioma (MPM) that cannot be removed with surgery. In ...
The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...